Results 251 to 260 of about 340,267 (341)

Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa‐Therapy in Parkinson's Disease: A Randomized, Placebo‐Controlled Study (PREMANDYSK)

Movement Disorders, EarlyView.
Abstract Objective Investigate the efficacy of immediate‐release (IR) amantadine in reducing the risk of peak‐dose dyskinesia in early Parkinson's disease (PD) as add‐on to levodopa. Background While the use of amantadine to manage dyskinesia in PD is well supported by controlled clinical trials, data on its efficacy in patients without motor ...
Olivier Rascol, Fabienne Ory‐Magne, Wassilios G. Meissner, David Maltête, Luc Defebvre, Jean‐Philippe Azulay, Stéphane Thobois, Jean‐Luc Houeto, Claire Thalamas, Agnès Sommet, Christian Geny, Philippe Damier, Mathieu Anheim, Ana Marquès, François Viallet, Maurice Giroud, Romain Lefaucheur, Guillaume Costentin, Umberto Spampinato, Alexandra Samier‐Foubert, Nicolas Carrière, Eugénie Mutez, Louise‐Laure Mariani, Alexandre Eusebio, Stéphane Prange, Isabelle Benatru, Mahmoud Charif, Christine Brefel‐Courbon, Margherita Fabbri, Monique Galitzky, Vanessa Rousseau, Amandine Saubion, Hélène Catala, Joaquim J. Ferreira, David J. Burn, Jean‐Christophe Corvol, on behalf of the PREMANDYSK Study Group, Olivier Rascol, Fabienne Ory‐Magne, Claire Thalamas, Jean‐Christophe Corvol, Luc Defebvre, Wassilios G Meissner, David Maltête, Jean‐Philippe Azulay, Jean‐Luc Houeto, Stéphane Thobois, François Viallet, Alexandra Samier‐Foubert, Umberto Spampinato, Thomas Boraud, François Tison, Franck Durif, Ana Marques, Bérengère Debilly, Stéphane Bernard, Maurice Giroud, Nicolas Carrière, Eugénie Mutez, Frederic Torny, Philippe Couratier, Oliver Colin, Thomas Gaudin, Pierre Boutet, Emmanuel Broussolle, Stéphane Prange, Cathrine Caire, Hélène Merle, Alexandre Eusebio, Manel Nouira, Christian Geny, Mahmoud Charif, Philippe Damier, Pascal Derkinderen, Mirela Faighel, Violaine Talmant, Severine LeDily, Louise‐Laure Mariani, Lucette Lacomblez, Anne‐Marie Bonnet, Isabelle Benatru, Jean‐Luc Houeto, Solène Ansquer, Emilie Rabois, Anne Fradet, Romain Lefaucheur, Guillaume Costentin, Linda Vernon, Christine Tranchant, Matthieu Anheim, Ouhaid Lagha‐Boukbiza, Thomas Wirth, Agnès Sommet, Vanessa Rousseau, Hélène Catala, Monique Galiztky, Amandine Saubion, Christine Brefel‐Courbon, Margherita Fabbri, Nadéra Ainaoui, Estelle Dellapina, Alexandra Salis, Frédéric Eyvrard, Camille Jurado, Nicolas Boulloche, Jany Rey‐Zermati, Jean Jaques Boulesteix   +106 more
wiley   +1 more source

Pilot Clinical Trial of Fecal Microbiota Transplantation for Constipation in Parkinson's Disease. [PDF]

J Microbiol Biotechnol
Zhang H, Shen C, Lei W, Wang J, Liu J, Qiu Z.   +5 more
europepmc   +1 more source

Constipation-Silicea.

, 1881
E B Nash
openalex   +1 more source

Correction to: The Role of Food in the Treatment of Bowel Disorders: Focus on Irritable Bowel Syndrome and Functional Constipation [PDF]

openalex   +1 more source

Bipolar Disorder as a Long‐Term Risk Factor for Parkinson's Disease: A Nationwide Case–Control Study

Movement Disorders, EarlyView.
Abstract Background Previous studies suggest an association between bipolar disorder (BD) and an increased risk of Parkinson's disease (PD), but the long‐term temporal relationship remains unclear. Particularly, it is unclear whether the risk of PD is influenced by the duration since BD diagnosis.
Elina Jaakkola, Marjaana Koponen, Valtteri Kaasinen, Jarmo Hietala, Sirpa Hartikainen, Anna‐Maija Tolppanen   +5 more
wiley   +1 more source

The impact of constipation management on the quality of life of Alzheimer’s patients [PDF]

Viacheslav Viktorovich Sushko, Viktor Vasilievich Sushko, Viktor Vasilievich Sushko, Viktor Vasilievich Sushko   +3 more
openalex   +1 more source

Early Autonomic Burden in Prodromal Parkinson's Disease Predicts Cognitive Impairment

Movement Disorders, EarlyView.
Abstract Background Autonomic dysfunction is a known contributor to cognitive impairment in Parkinson's disease (PD), but its impact during prodromal stage is unknown. Objective The aim was to determine whether early autonomic burden predicts incident cognitive impairment in prodromal PD.
A. Enrique Martinez‐Nunez, Kelly A. Mills, Joseph Seemiller, Christopher B. Morrow, Gregory M. Pontone, Abhimanyu Mahajan   +5 more
wiley   +1 more source

Phase 3b Extension Study MT‐1186‐A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is currently approved in the US for treatment of amyotrophic lateral sclerosis (ALS). Placebo‐controlled clinical trials showed that IV edaravone slows physical functional decline.
Angela Genge, Jeffrey Rothstein, Shari De Silva, Lorne Zinman, Marvin Chum, Adriano Chiò, Gen Sobue, Masashi Aoki, Hiide Yoshino, Manabu Doyu, Daniel Selness, Vesna Todorovic, Manabu Hirai, Nissim Sasson, Fumihiro Takahashi, Michelle Cecić, Art Wamil, Stephen Apple   +17 more
wiley   +1 more source

Evaluation of Constipation and Quality of Life Among Individuals Undergoing Hemodialysis: A Single-Center Cross-Sectional Study. [PDF]

Healthcare (Basel)
Fatani A, Shafi RW, Alhozali H, Alam FMA, Daghistani AM, Mat Daud ZA, Tashkandi B, Aljehany B.   +7 more
europepmc   +1 more source

β3‐Adrenoceptor Agonists for Neurogenic Lower Urinary Tract Dysfunction: Evidence and Clinical Rationale for First‐Line Therapy

Neurourology and Urodynamics, EarlyView.
ABSTRACT Aims To summarize current evidence on β3‐adrenoceptor agonists for managing neurogenic lower urinary tract dysfunction (NLUTD), focusing on their efficacy, safety, and clinical role in optimizing bladder storage and protecting upper tracts. Methods Evidence from randomized controlled trials, meta‐analyses, and observational studies in spinal ...
Sharon E. Fishberg, Rano Matta
wiley   +1 more source